Determination of plasma protein binding of dalbavancin.

Loading...
Thumbnail Image

Date

2022-06

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

0
views
2
downloads

Citation Stats

Abstract

Objectives

Dalbavancin is a lipoglycopeptide with a long half-life, making it a promising treatment for infections requiring prolonged therapy, such as complicated Staphylococcus aureus bacteraemia. Free drug concentration is a critical consideration with prolonged treatment, since free concentration-time profiles may best correlate with therapeutic effect. In support of future clinical trials, we aimed to develop a reliable and reproducible assay for measuring free dalbavancin concentrations.

Methods

The ultracentrifugation technique was used to determine free dalbavancin concentrations in plasma at two concentrations (50 and 200 mg/L) in duplicate. Centrifuge tubes and pipette tips were treated for 24 h before use with Tween 80 to assess adsorption. Dalbavancin concentrations were analysed from the plasma samples (total) and middle layer samples (free) by LC/MS/MS with isotopically labelled internal standard. Warfarin served as a positive control with known high protein binding.

Results

Measurement of free dalbavancin was sensitive to adsorption onto plastic. Treatment of tubes and pipette tips with ≥2% Tween 80 effectively prevented drug loss during protein binding experiments. By the ultracentrifugation method, dalbavancin's protein binding was estimated to be approximately 99%.

Conclusions

Dalbavancin has very high protein binding. Given dalbavancin's high protein binding, accurate measurement of free dalbavancin concentrations should be a key consideration in future exposure-response studies, especially clinical trials. Future investigations should confirm if the active fraction is best predicted by the free or total fraction.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.1093/jac/dkac131

Publication Info

Turner, Nicholas A, Allan Xu, Smitha Zaharoff, Thomas L Holland and Thomas P Lodise (2022). Determination of plasma protein binding of dalbavancin. The Journal of antimicrobial chemotherapy, 77(7). pp. 1899–1902. 10.1093/jac/dkac131 Retrieved from https://hdl.handle.net/10161/29595.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Turner

Nicholas Turner

Assistant Professor of Medicine
Holland

Thomas Lawrence Holland

Associate Professor of Medicine

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.